SCHEMBL563902

SCHEMBL563902

Nc1cc(Nc2cccc(O)c2)ccc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.62
TSHR P16473 1/20 0.62
HDAC6 Q9UBN7 1/20 0.52
KMT2A Q03164 5/20 0.49
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 3/20 0.49
ALOX15 P16050 2/20 0.49
CYP1A2 P05177 2/20 0.49
MAPT P10636 2/20 0.49
USP2 O75604 1/20 0.49
APP P05067 1/20 0.49
HSP90AA1 P07900 1/20 0.49
HSP90AB1 P08238 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
ALOX12 P18054 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP2C19 P33261 1/20 0.49
SNCA P37840 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17508253 0.89 CYP3A4 (0.62) CYP3A4TSHRHDAC6KMT2AALDH1A1
SCHEMBL564678 0.88 ALDH1A1 (0.50) CYP3A4TSHRKMT2AALDH1A1MEN1
SCHEMBL564726 0.87 CYP3A4 (0.60) CYP3A4TSHRHDAC6KMT2AALDH1A1
SCHEMBL564967 0.87 MAPT (0.60) CYP3A4TSHRKMT2AALDH1A1MEN1
SCHEMBL564969 0.86 CYP3A4 (0.59) CYP3A4TSHRKMT2AALDH1A1MEN1
SCHEMBL563872 0.84 ALDH1A1 (0.61) CYP3A4TSHRKMT2AALDH1A1MEN1
SCHEMBL17508260 0.84 RAPGEF4 (0.57) CYP3A4TSHRHDAC6KMT2AALDH1A1
SCHEMBL1920769 0.83 CYP3A4 (0.86) CYP3A4TSHRHDAC6KMT2AALDH1A1
SCHEMBL1389429 0.83 CYP3A4 (0.86) CYP3A4TSHRHDAC6KMT2AALDH1A1
SCHEMBL30026816 0.83 CYP3A4 (0.86) CYP3A4TSHRHDAC6KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674029-B2 Method of preparing stabilized polymeric systems using polymeric peroxides Sunocs LLC (US) 2014-03-18 US disclosed
US-20120035307-A1 PROCESS FOR MAKING STABLIZED POLYMERIC SYSTEMS WITH NANOSTRUCTURES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-20120035315-A1 METHOD OF PREPARING STABLIZED POLYMERIC SYSTEMS USING POLYMERIC PEROXIDES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-7498467-B2 Antioxidant and bisaminophenol derivative IDEMITSU KOSAN CO., LTD. (JP) 2009-03-03 US disclosed
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-07-03 US disclosed
US-20060208227-A1 Antioxidant and bisaminophenol derivative IDEMITSU LOSAN CO., LTD (JP) 2006-09-21 US disclosed
EP-1612254-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE CBR1, CBR3, HMOX1 CYP3A4 360/4885TSHR 2375/4885HDAC6 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.